NCT01938378 - Octaplas Pediatric Plasma Exchange Trial | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

January 27, 2019

Study Completion Date

January 27, 2019

Conditions

Adverse Effects in the Therapeutic Use of Plasma Substitutes

Interventions

BIOLOGICAL

Octaplas™

octaplas™ infusion solution for IV administration, ABO compatibile. Recommended dose for a plasma exchange is 40 to 60 ml/kg.

Trial Locations (8)

Octapharma Research Site, Durham

Octapharma Research Site, Atlanta

Octapharma Research Site, Birmingham

Octapharma Research Site, Cincinnati

Octapharma Research Site, Minneapolis

Octapharma Research Site, St Louis

Octapharma Research Site, Kansas City

Octapharma Research Site, New Orleans